A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2018
At a glance
- Drugs Lisocabtagene-maraleucel (Primary)
- Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms TRANSCEND-NHL-006
- Sponsors Juno Therapeutics
- 12 Jul 2018 Status changed from not yet recruiting to recruiting.
- 06 Jun 2018 Planned initiation date changed from 2 May 2018 to 2 Jul 2018.
- 04 Apr 2018 Planned End Date changed from 2 Apr 2021 to 2 May 2021.